The company is a leading provider of an AI-powered precision oncology platform transforming biomarker discovery and treatment decisions. Nucleai’s platform leverages unique tissue datasets to produce insights into cancer biology, increasing clinical trial efficacy, and improving patient care. Nucleai works with leading pharmaceutical companies, licensing its research platform for internal use, and collaborating in biomarkers discovery projects.
Total Funding: $11.5 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2017
For AI Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI Startup founders or founders at Nucleai
Avi Veidman
CEO
Eliron Amir
COO
Albert Achtenberg
CTO
Nucleai - AI Startup | AI Startup Profile Powered by Appengine AI | Appengine AI - AI Ecosystem of 12,000+ AI Startups
Nucleai - Manage Profile
World's Most Promising AI Startups
World's Leading AI Ecosystem of AI Startups, Founders, Investors, and AI Professionals
Get Started